In its first full year on the commercial market, the SyncThink platform has been widely adopted by top healthcare organizations, professional sports teams, and NCAA athletic programs, the company notes.
The SyncThink platform also recently received Breakthrough Device Designation from the FDA for providing objective measurements to aid in the assessment of concussion, the company announces.
Throughout 2018, SyncThink has evolved the utility of its platform. Originally designed for rapid visual assessments, the proprietary EYE-SYNC technology now covers the full spectrum of brain performance to detect ocular and vestibular impairments, provide the necessary recovery interventions, and further improve dynamic vision as a training tool.
“2018 has been an exciting year for us – as we’ve proven our clinical utility we’ve dramatically grown the business and usage metrics,” says Laura Yecies, CEO, in a media release. “Clinicians and performance specialists alike are appreciating the utility of objective metrics for brain health and the ability to enhance individual and team performance.”
In addition to significant product growth, SyncThink has expanded its commercial presence in North America with 40 user locations, as well as over 200 clinicians utilizing EYE-SYNC in the care of their patient population. The use of the technology within these sites varies from almost 30,000 baseline assessments performed, over 2,000 discrete injury assessments, and over 5,900 post-injury assessments and treatments provided during the year. SyncThink also continues to maintain what the company reports as the world’s largest eye tracking database with over 50,000 patient results.
In addition to both product and commercial growth, the advisory board at SyncThink has also grown to include prominent athletes such as Hall of Fame Quarterback Steve Young and former MLS Star Taylor Twellman. The company also recently announced its development partnership with Magic Leap as it focuses in 2019 on the expansion of its platform capabilities, the release continues.
For more information, visit SyncThink.
[Source: SyncThink]
